Among the antibiotics developed, Cephalospoirn is very much crucial to fight against contagious diseases
especially for life threatening (serious) infections. But dedicated manufacturing facility is required to produce
Cephalosporin in order to prevent any cross contamination.
TIME pharmaceuticals P. Ltd. has built a State-of-the-art Cephalosporin plant in its premises at Gaindakot-10,
Nawalparasi. The plant has been designed with the strict adherence to WHO cGMP guidelines. Untouched and
online technology from air jet washing to powder filling, induction sealing and capping, individual weight and
sealing, checking and sicker labeling of dry powder for reconstitution assures the best quality and safety avoiding
cross contamination and unwilling contact with chemical that may cause sensitive reaction to its people directly
involved in manufacturing procedure.
With the plan for different generation products of Cephalosporin and newest generation of cephalosporin, TIME
plans to provide strong portfolios for therapeutic management of bacterial infections. TIME will continue
producing and enriching its portfolios by adding new generations and derivatives by considering the patients
benefit in the day going on. According to WHO cGMP, cross contamination between beta lactam and non beta
lactam products should be avoided and cross contamination between penicillin beta lactam and non penicillin
beta lactum should be avoided.
WHO cGMP requires a separate manufacturing facility for penicillin beta lactam and non-penicillin beta lactam
products. Separate manufacturing facility means seperte building, separate air handling units (HVAC system),
separate equipments, separate utilities and separate staff.